<DOC>
	<DOCNO>NCT00043641</DOCNO>
	<brief_summary>This study investigate low-level viral load HIV-infected patient take highly active antiretroviral therapy ( HAART ) . Although HAART reduce viral level restore immune function degree , cure HIV infection . The virus persist even level detect . This study examine residual virus come order well understand infection effectiveness therapy . In addition , study 1 ) evaluate ability new test detect virus low level ; 2 ) determine whether add protease inhibitor Kaletra HAART treatment regimen patient low viral load decrease viral load . HIV-infected patient 18 year age old may eligible study . Patients involved viral load test recruit NIAID HIV study already participate . Three group patient enrol : viral load le 50 copies/ml plasma , 51-500 copies/ml , 501-5000 copies/ml . Patients involve Kaletra trial must take HAART 6 month le 50 viral copies/ml plasma . They screen study history , physical examination , routine laboratory test . Participants viral load test evaluation donate 70 ml blood four time . No one sample collect per day . Participants Kaletra trial blood sample draw two successive day randomly assign one two treatment group . One group begin Kaletra therapy ( four capsule two time day ) immediately ; undergo observation 4 week start Kaletra . Depending group , patient provide blood sample viral load measurement clinical sample accord follow schedule : Immediate Kaletra One sample week 1 , 2 , 3 , therapy two sample week 4 . Delayed Kaletra One sample week 1 , 2 , 3 observation two sample week 4 . After start therapy , one sample collect week week 1 , 2 , 3 therapy two sample week 4 . In group , last dose medicine day 28 , Kaletra therapy complete . At end therapy , additional blood collect viral sampling follow : one sample week 1 , 2 , 3 , two sample week 4 Kaletra therapy .</brief_summary>
	<brief_title>HIV Expression Patients With Low Viral Load Highly Active Antiretroviral Therapy ( HAART )</brief_title>
	<detailed_description>This protocol exploratory study HIV expression patient receive highly active antiviral therapy low viral load near current limit detection ( 50 copies/ml plasma ) . Recent study suggest patient suppressed viral load low range continue HIV expression , amount origin virus remain unknown . The amount virus expression plasma uncertain current viral load assay imprecise cutoff range 50-75 copies/ml plasma . The origin HIV find low viral load detect unknown well ; two possible source virus include expression long-lived reservoir infect cell , low level spread infection uninfected cell . Determining origin HIV expression clinical importance ; currently available HIV drug therapy little effect HIV expression establish reservoir , potent HIV therapy could potentially inhibit spread HIV infection . In study plan two principal objective . First , investigate level HIV expression plasma sample low viral load use new HIV load assay enhance sensitivity precision viral load range 1-100 copy . If data survey confirm acceptable performance characteristic assay proceed stage II protocol . In stage II plan determine , several short-term intensification approach investigate whether incorporation additional antiretroviral suppressive HAART regimens ( `` intensification HAART '' ) suppress plasma virus . In small pilot study , plan intensify regimens 30 day nonrandomized fashion . Secondly , plan study patient switch medication preference mild toxicity . In patient intensify regimens 30 day overlap fashion , add new drug instead switch medication . After 30 day drug overlap , continue new drug discontinue identify antiretroviral . These initial study assist obtain initial data confirm estimate sample size large , randomize study rigorously investigate virologic effect drug intensification . If initial proof-of-concept experiment suggest HIV may suppress intensification HAART , plan expand study large control trial determine degree suppression possible intensification therapy . As secondary objective investigate whether feasible study HIV genetic variation sample patient suppress viral load use molecular technique develop study HIV variation patient viral load great 1000 copies/ml plasma ( protocol 00-I-0110 ) . We plan enroll 70 patient viral load survey cohort HIV viral load , analyze series sample complete trial antiretroviral therapy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>INCLUSION CRITERIA : VIRAL SURVEY COHORT HIV1 infection document HIV ELISA WB Age great equal 18 year old Hemoglobin great equal 12 mg/dl within last six week On HAART accord current DHHS guideline . Most recent viral load ( within last 12 week ) : le 50 bDNA RTPCR ( 65 patient ) 50500 bDNA RTPCR ( 3 patient ) 501 10,000 bDNA RTPCR ( 2 patient ) EXCLUSION CRITERIA : Any febrile illness ( T great 38.0 degree C ) 3 week prior blood draw . VIRAL SURVEY COHORT M98863 , M97720 , AACTG 5201 SAMPLES ( inclusion/exclusion ) : Samples patient enrol complete M98863 , M97720 AACTG 5201 study . INCLUSION CRITERIA : PILOT INTENSIFICATION COHORT : HIV1 infection document HIV ELISA WB Age great equal 18 year old Hgb great equal 12 mg/dl CD4 great 200 cells/ micro liter CD4 % great 14 % require prophylaxis opportunistic infection Therapy accept HAART regimen great equal 6 month Viral load le 50 copy RNA/ml plasma RTPCR least four month Viral load great 0.38 copy RNA/ml plasma SCA assay positive adapt Amplicor assay Current HAART DHHSapproved regimen NRTI+PI , NRTI alone , NRTI+NNRTI . Willingness take additional antiretroviral current regimen 30 day . For patient start lopinavir/ritonavir , willingness reduce dose sildenafil coadministered medicine may affect addition lopinavir/ritonavir course therapy lopinavir/ritonavir For patient start efavirenz arm , willingness take efavirenz adjust medication supplement necessary , aware efavirenz contraindicate pregnancy may result false positive urine test THC For patient start raltegravir , prior history rhabdomyolysis coadministration agent , opinion investigator , would cause rhabodomyolysis myopathy . Patient must primary care outside protocol . Patients must practice accept barrier method prevent pregnancy . For patient enrol piolt study suppression development resistance , patient must document evidence prior drug resistance either : Prior resisteance test presence resisnce mutation document evidence viral RNA level great 100 copies/ml plasma great 6 month despite antiretroviral thereapy . Patients prior therapy monotherapy suboptimal combination therapy ARE eligible study . INCLUSION CRITERIA : RANDOMIZED INTENSIFICATION COHORT ( NIH , University Pittsburgh ) : HIV1 infection document HIV ELISA WB Age great equal 18 year old Hgb great equal 12 mg/dl CD4 great 200 cells/ micro liter CD4 % great 14 % require prophylaxis opportunistic infection Therapy accept HAART regimen great equal 6 month . Viral load le 50 copy RNA /ml plasma RTPCR least four month . Viral load great equal 0.38 copy RNA/ml plasma SCA assay positive adapt Amplicor assay Current HAART DHHSapproved regimen NRTI+PI , NRTI alone , NRTI+NNRTI . Willingness take additional antiretroviral current regimen 30 day . For patient start lopinavir/ritonavir , willingness reduce dose sildenafil coadministered medicine may affect addition lopinavir/ritonavir course therapy lopinavir/ritonavir For patient start efavirenz arm , willingness take efavirenz adjust medication supplement necessary , aware efavirenz contraindicate pregnancy may result false positive urine test THC Patient must primary care outside protocol . Patients must practice accept barrier method prevent pregnancy . EXCLUSION CRITERIA : Requirement cytotoxic agent include hydroxyurea vaccination study period Chronic corticosteroid therapy Concurrent therapy investigational cytokine include IL2 IL12 course study . Prior administration cytokine exclusion criterion ; least 4 month recent cycle IL2 IL12 . GCSF erythropoietin therapy permit History take salvage regimen ; i.e. , patient clinical resistance antiretrovirals . Changing antiviral therapy adverse effect permit Prior PI therapy NNRTI therapy permit unless previous PIcontaining therapy switch patient preference . If patient document history lipid elevation ( fast triglyceride great 750 mg/dl ) , patient eligible PI addition . Any febrile illness ( T great 38.0 degree C ) 3 week prior enrollment Any vaccination 6 week prior enrollment Current pregnancy lactation , history pregnancy last 4 month Prior history intolerance add antiretroviral For lopinavir/ritonavir addition , baseline elevate triglyceride great 400 mg/dl without lipid lower agent Elevated baseline ALT liver function assay great 2 fold great upper limit normal Known history liver disease ChildPugh score great 5 . History pancreatitis require hospitalization Concomitant use drug highly dependent cytochrome P450 clearance , , opinion investigator , may lead unexpected change concentration occur addition lopinavir/ritonavir efavirenz . Examples include limited : wafarinlike anticoagulation , amiodarone , astemizole , cisapride , statin class drug , gemfibrozil , cyclosporine , ergonavine , ergotamine , methylergonavine , dihydroergotamine , dofetilide , flecanide , quinidine , fusidic acid , methadone , demerol , midazolam , triazolam , phenytoin , dilantin , pimozide , sirolimus , tacrolimus , propafenone , quinupristin , terfenadine , theophylline , rifampin , rifapentene , rifabutin illicit substance , include recreational substance ( ecstasy ) methylenedioxymethamphetamine . History chronic diarrhea inflammatory bowel disease History hemophilia Inability comply protocol For start efavirenz , significant depression , , opinion investigator , would significantly worsen efavirenz . INCLUSION CRITERIA DRUG OVERLAP COHORT : HIV1 infection document HIV ELISA WB Age great equal to18 year old Hgb great equal 12 mg/dl CD4 great 200 cells/ micro liter CD4 % great 14 % require prophylaxis opportunistic infection Therapy accept HAART regimen great equal 6 month Viral load le 50 copy RNA/ml plasma RTPCR least four month Viral load great 0.38 copy RNA/ml plasma SCA assay positive adapt Amplicor assay Current HAART DHHSapproved regimen NRTI+PI , NRTI alone , NRTI+NNRTI Willingness take additional antiretroviral current regimen 30 day For patient plan start lopinavir/ritonavir , ritonavir contain regimen willingness reduce dose sildenafil coadministered medicine may affect addition ritonavir course therapy lopinavir/ritonavir For patient start efavirenz , willingness take efavirenz adjust medication supplement necessary , aware efavirenz contraindicate pregnancy may result false positive urine test THC Patient must primary care outside protocol Patients must practice accept barrier method prevent pregnancy . EXCLUSION CRITERIA : Requirement cytotoxic agent include hydroxyurea vaccination study period Chronic corticosteroid therapy Concurrent therapy investigational cytokine include IL2 IL12 course study . Prior administration cytokine exclusion criterion ; least 4 month recent cycle IL2 IL12 . GCSF erythropoietin therapy permit History take salvage regimen ; i.e. , patient clinical resistance antiretrovirals . Changing antiviral therapy adverse effect permit Prior PI therapy NNRTI therapy permit unless previous PIcontaining therapy switch patient preference . If patient document history lipid elevation ( fast triglyceride great 750 mg/dl ) patient eligible PI addition . Any febrile illness ( T great 38 degree C ) 3 week prior enrollment Any vaccination 6 week prior enrollment Current Pregnancy lactation , history pregnancy last 4 month Prior history intolerance add antiretroviral For protease addition , baseline elevate triglyceride great 400 mg/dl without lipid lower agent Elevated baseline ALT liver function assay great 2 fold great upper limit normal Known history liver disease ChildPugh score great 5 . History pancreatitis require hospitalization For patient add ritonavir efavirenz , concomitant use drug highly dependent cytochrome P 450 clearance , , opinion investigator , may lead unexpected change concentration occur new drug add . Examples include limited : wafarinlike anticoagulation , amiodarone , astemizole , cisapride , statin class drug , gemfibrozil , cyclosporine , ergonavine , ergotamine , methylergonavine , dihydroergotamine , dofetilide , flecanide , quinidine , fusidic acid , methadone , demerol , midazolam , triazolam , phenytoin , dilantin , pimozide , sirolimus , tacrolimus , propafenone , quinupristin , terfenadine , theophylline , rifampin , rifapentene , rifabutin illicit substance , include recreational substance ( ecstasy ) methylenedioxymethamphetamine History chronic diarrhea inflammatory bowel disease History hemophilia Inability comply protocol For start efavirenz , significant depression , , opinion investigator , would significantly worsen efavirenz</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 7, 2013</verification_date>
	<keyword>RT PCR</keyword>
	<keyword>Antiretrovial Therapy</keyword>
	<keyword>Drug Intensification</keyword>
	<keyword>Ultra-low</keyword>
	<keyword>Sequence</keyword>
	<keyword>HIV</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>